Browse

browse by

22records

C17orf91

alias symbols:

tissues ovary

cancer type ovarian cancer

LncRNA C17orf91 expression is elevated in omental metastases when compared with matched primary ovarian tumors. Increased expression of C17orf91 is associated with shorter progression- free survival. C17orf91 inhibition significantly decreases migration, invasion and viability of Hey cells. Mechanistically, C17orf91 repression could reduce the expression of KLF8 and SNAI2 at mRNA level, and reduce MYC at both protein and mRNA level.


C21orF96

alias symbols:

tissues stomach

cancer type gastric cancer

LncRNA C21orF96 is over-expressed in positive lymph node and gastric cancer tissues, and associated with gross appearance, lymphatic metastasis and distal metastasis. Further studies find that C21orF96 promotes the tubular formation, migration and invasion.


CADM1-AS1

alias symbols:

tissues kidney

cancer type renal clear cell cancer

LncRNA CADM1-AS1 is down-regulated and correlated with the mRNA expression of CADM1 in clear cell renal cell carcinoma (ccRCC) tissues. Decreased CADM1-AS1 expression is associated with more advanced AJCC stage and is an independent predictor for overall survival. Moreover, CADM1-AS1 can prohibit cancer cell proliferation, migration, and promote apoptosis.


CAHM

alias symbols:

tissues colorectum

cancer type colorectal cancer

LncRNA CAHM is hypermethylation in neoplastic colorectal tissue, and blood from CRC patients. CAHM methylation correlates with of loss expression of CAHM RNA in colorectal tissue and CRC cell lines. Moreover, CAHM methylation levels in blood reflect disease severity.


CAR10

alias symbols:

tissues lung

cancer type xuanwei lung cancer

LncRNA CAR10 is up-regulated in Xuanwei lung cancer patients. CAR10 overexpression is associated with air pollution. A smoky coal combustion-generated carcinogen dibenz[a,h]anthracene up-regulates CAR10 by increasing transcription factor FoxF2 expression. CAR10 binds and stabilizes transcription factor Y-box-binding protein 1 (YB-1), leading to upregulation of the epidermal growth factor receptor (EGFR) and proliferation of lung cancer cells. Moreover, CAR10 can promote cell growth and tumor growth.


CASC11

alias symbols:

tissues colorectum

cancer type colorectal cancer

LncRNA CASC11 is up-regulated in colorectal cancer (CRC) tissues and increased CASC11 expression in CRC is associated with tumor size, serosal invasion, lymph metastasis, and the tumor–node–metastasis (TNM) stage. Functional experiments show that CASC11 can promote CRC cell proliferation and metastasis. Furthermore, CASC11 can target heterogeneous ribonucleoprotein K (hnRNP-K) to activate WNT/β-catenin signaling in CRC cells. In addition, c-Myc can directly bind to the promoter regions of CASC11 and increase promoter histone acetylation to enhance CASC11 expression.


CASC15

alias symbols:

tissues others

cancer type melanoma

LncRNA CASC15 RNA is up regulated in melanoma lines and up-regulated in a xenograft model of melanoma brain metastasis. RACE identifies an alternative CASC15 transcriptional start site and multiple splice variants. Moreover, CASC15 levels increase during melanoma progression and its expression in melanoma LN metastases is an independent predictor of disease recurrence and survival. Besides, siRNA knockdown experiments reveal that CASC15 regulates melanoma cell phenotype switching between proliferative and invasive states.


CASC2

alias symbols:

tissues colorectum,kidney,lung,nervous system

cancer type colorectal cancer,glioma,non-small-cell lung cancer,renal cancer

LncRNA CASC2 is lower in colorectal cancer, glioma, renal cell carcinoma, non-small cell lung cancer (NSCLC). Its expression level is associated with clinicopathological parameters such as tumor size, TNM stage, prognosis etc.. Functionally, CASC2 regulates cancer cell proliferation, migration, metastasis, invasion and apoptosis. Mechanistically, CASC2 can bind to miR-18a, miR-21. Besides, CASC2 negatively regulates pSTAT3 and c-Myc.


CASC8

alias symbols:

tissues lung

cancer type lung cancer

The single nucleotide polymorphisms (SNP) CASC8 rs10505477 is greatly related to lung cancer risk in male and adenocarcinoma subgroups in recessive model. It is also closely correlated with platinum-based chemotherapy response in dominant model. Additionally, CASC8 rs10505477 polymorphism is significantly relevant to severe hematologic toxicity in non-small-cell lung cancer (NSCLC) subgroup in dominant model and in additive model. Furthermore, rs10505477 polymorphism is greatly associated with gastrointestinal toxicity in small cell lung cancer (SCLC) and cisplatin subgroups in dominant model.


CASC9

alias symbols:

tissues esophagus

cancer type esophageal squamous cell cancer

LncRNA CASC9 is markedly up-regulated in esophageal squamous cell carcinoma (ESCC) tissues and cell lines. Furthermore, knockdown of CASC9 significantly suppresses cell migration and invasion. Besides, enhanced CASC9 expression level is correlated with differentiation.


CCAL

alias symbols:

tissues colorectum

cancer type colorectal cancer

LncRNA CCAL is up-regulated in colorectal cancer (CRC) tissues and high CCAL level is associated with poor overall survival and a worse response to adjuvant chemotherapy. Further studies reveal that CCAL promotes CRC progression by targeting activator protein 2α (AP-2α), which in turn activates Wnt/β-catenin pathway. Moreover, CCAL induces multidrug resistance (MDR) through activating Wnt/β-catenin signaling by suppressing AP-2α and further up-regulating MDR1/P-gp expression. In addition, histone H3 methylation and deacetylases contribute to the upregulation of CCAL in CRC.


CCAT1

alias symbols:

tissues bone marrow,breast,colorectum,endometrium,gallbladder,liver,lung,stomach

cancer type acute myelocytic leukemia,breast cancer,colorectal cancer,endometrial cancer,gallbladder cancer,gastric adenocarcinoma,gastric cancer,hepatic cancer,non-small-cell lung cancer

LncRNA CCAT1 is higher in breast cancer, colorectal cancer, gallbladder cancer, gastric cancer and hepatocellular carcinoma. CCAT1 expression level is associated with clinicopathological parameters such as differentiation grade, TNM stage, lymph node metastases, prognosis etc.. Functionally, CCAT1 regulates cancer cell proliferation, migration, metastasis, invasion and apoptosis. Further studies reveal that CCAT1 can bind to miRNA-218-5p, c-Myc and let-7. Moreover, CCAT1 can negatively regulate Bmi1, miR-490 and positively regulate c-Myc, HMGA2 and hnRNAP1.


CCAT2

alias symbols:

tissues breast,cervix,colorectum,esophagus,liver,lung,ovary,stomach

cancer type breast cancer,cervical cancer,cervical squamous cell cancer,colorectal cancer,esophageal squamous cell cancer,gastric cancer,hepatic cancer,lung cancer,non-small-cell lung cancer,ovarian cancer

LncRNA CCAT2 is higher in breast cancer, esophageal squamous carcinoma, lung cancer, gastric cancer, cervical cancer and ovarian cancer. CCAT2 expression level is associated with clinicopathological parameters such as lymph node metastasis, TNM stage, prognosis etc.. Functionally, CCAT2 regulates cancer cell proliferation, migration, metastasis, invasion and apoptosis. Besides, CCAT2 is involves with chemotherapy response.


CCDC26

alias symbols:

tissues bone marrow,pancreas

cancer type myeloid leukemia,pancreatic cancer

LncRNA CCDC26 is higher in pancreatic cancer (PC) cells and tissues. CCDC26 expression is correlated with tumor size and tumor number. Patients with higher CCDC26 expression have shorter overall survival time. Knockdown of CCDC26 suppresses PC cells proliferation and induces apoptosis via suppressing PCNA and Bcl2. In leukemia cell lines, CCDC26 is expressed in cells derived from acute myelocytic leukemia (AML), acute monocytic leukemia and chronic myelogenous leukemia (CML). Very low expression is observed in megakaryoblastic cells derived from leukemia accompanied with Down’s syndrome (C...


CCHE1

alias symbols:

tissues cervix

cancer type cervical cancer

LncRNA CCHE1 is up-regulated in cervical cancer tissues and predicts poor prognosis of cervical cancer patients. Correlation regression analysis shows that increased CCHE1 expression is significantly correlated with larger tumor size, advanced FIGO stage, higher SCC-Ag and uterine corpus invasion. CCHE1 promotes the proliferation of cervical cancer cells and the effect is dependent upon CCHE1 physically associating with PCNA mRNA thus to up-regulate the expression of PCNA.


CLMAT3

alias symbols:

tissues colorectum

cancer type colorectal cancer

LncRNA CLMAT3 is generally increased in human colorectal cancer (CRC) cell lines. Knockdown of CLMAT3 in CRC cells decreases cell growth, inhibits CRC cell cycle progression and induces apoptosis. Master G0/G1 regulators including Cdh1, CDKN1B (p27Kip1) and Skp2 are measured after CLMAT3 knockdown. The results show an increased Cdh1 expression by accelerating Skp2 degradation, which results in p27Kip accumulation.


CPS1-IT1

alias symbols:

tissues liver,others

cancer type hepatic cancer,intrahepatic cholangiocarcinoma

LncRNA CPS1-IT1 is down-regulated in hepatocellular carcinoma and up-regulated in intrahepatic cholangiocarcinoma. It can affect cancer cell proliferation, migration and apoptosis. Besides, it can inhibit EMT of hepatocellular carcinoma cells.


CRNDE

alias symbols:

tissues colorectum,nervous system

cancer type colorectal cancer,glioma

LncRNA CRNDE is higher in glioma. CRNDE overexpression facilitates cell proliferation, migration, and invasion, while inhibits glioma cells apoptosis. CRNDE can bind to miR-384 and miR-186, and suppress their function. CRNDE knockdown results in a decrease of piwi-like RNA-mediated gene silencing 4 (PIWIL4) protein. Meanwhile, CRNDE decreases the expression levels of XIAP and PAK7 by binding to miR-186 and negatively regulating it. Exon microarrays shows substantially elevated expression across exons E2, E4, In4, E5, In5 and part of E6 of CRNDE in colorectal cancer tissues. Transcript isof...


CTB-89H12.4

alias symbols:

tissues prostate

cancer type prostate cancer

LncRNA CTB-89H12.4 is up-regulated in prostate cancer cell lines. Depletion of PTEN transcript by siRNAs reduces the expression of CTB-89H12.4. The depletion of CTB-89H12.4 transcripts also reduces the expression of two other protein-coding genes (PCGs), VAPA and SERINC1, sponge-mRNAs of PTEN.


CTBP1-AS

alias symbols:

tissues prostate

cancer type prostate cancer

LncRNA CTBP1-AS is an androgen-responsive long ncRNA, located in the antisense (AS) region of C-terminal binding protein 1 (CTBP1), which is a co-repressor for androgen receptor. CTBP1-AS is predominantly localized in the nucleus and its expression is generally up-regulated in prostate cancer. CTBP1-AS promotes both hormone-dependent and castration-resistant tumor growth. Mechanistically, CTBP1-AS directly represses CTBP1 expression by recruiting the RNA-binding transcriptional repressor PSF together with histone deacetylases. CTBP1-AS also exhibits global androgen-dependent functions by in...


CTD-2108O9.1

alias symbols:

tissues stomach

cancer type gastric cancer

LncRNA CTD-2108O9.1 is lower in gastric cancer tissues and cell lines. Moreover, the transwell assay shows that the number of cells capable of passing through the matrigel is significantly reduced after CTD-2108O9.1 transfection. However, CTD-2108O9.1 overexpression does not significantly influence cell proliferation and cell cycle progression. Lastly, western blot and real-time PCR analysis suggests that CTD-2108O9.1 is positively correlated with the expression of leukemia inhibitory factor receptor (LIFR) gene at the translational level.


CTD903

alias symbols:

tissues colorectum

cancer type colorectal cancer

LncRNA CTD903 expression is up-regulated in colorectal cancer tissues. The higher CTD903 group shows more percentages of colon cancers comparing with rectum cancers, less mucinous tumors, and smaller tumor size. CTD903 high expression group has a significantly longer recurrence-free survival (RFS). Overexpression of CTD903 impairs cell invasion, migration and proliferation. CTD903 represses Wnt/β-catenin signaling and inhibits EMT-associated transcription factors twist and snail expression.